{"id":"NCT01858948","sponsor":"University of Cincinnati","briefTitle":"SGA-induced Metabolic Syndrome in Bipolar Youth","officialTitle":"Risk and Protective Factors for SGA-induced Metabolic Syndrome in Bipolar Youth","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2018-04","completion":"2018-04","firstPosted":"2013-05-21","resultsPosted":"2022-11-25","lastUpdate":"2022-11-25"},"enrollment":19,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Youth Treated With Second-generation Antipsychotics"],"interventions":[{"type":"DRUG","name":"Omega","otherNames":["EPA+DHA supplements (OmegaRx)"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo supplements (corn oil) provided by the Inflammation Research Foundation"]},{"type":"DRUG","name":"Quetiapine fumarate","otherNames":["Seroquel"]}],"arms":[{"label":"Quetiapine plus Omega","type":"EXPERIMENTAL"},{"label":"Quetiapine plus Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The investigators tested the hypothesis that long-chain omega-3 (LCn-3) fatty acid supplementation will attenuate the adverse cardiometabolic effects of second-generation antipsychotics exposure in first-episode adolescent manic patients.","primaryOutcome":{"measure":"Body Mass Index (BMI)","timeFrame":"24 weeks","effectByArm":[{"arm":"Quitiapine Plus Omega","deltaMin":24.4,"sd":4.7},{"arm":"Quetiapine Plus Placebo","deltaMin":26.3,"sd":7.4}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":[]}}